Investing in the pharmaceutical industry has always been a risky venture, with constantly changing trends and advancements. However, Roundhill Investments’ recent move to launch the GLP-1 & Weight Loss ETF (OZEM) signifies a strong belief in the long-term potential of GLP-1 weight loss drugs. This ETF focuses on pairing established leaders like Eli Lilly and Novo Nordisk with emerging players in the market, who are developing innovative treatments for weight loss and diabetes.
According to Roundhill Investments’ CEO, Dave Mazza, the industry’s growth potential is exponential. By actively managing the ETF to allocate more weightage to companies actively producing these drugs, and identifying promising players in different phases of development, Mazza believes they can capitalize on the expected boom in the market. Eli Lilly and Novo Nordisk currently hold a significant 20% weighting each in the ETF, showcasing their dominance in the field.
Apart from the industry leaders, the GLP-1 & Weight Loss ETF also includes smaller players like Zealand Pharma, Amgen, and Chugai Pharmaceutical, each with a weighting below 5%. This diversification ensures that investors have exposure to various segments of the market and can benefit from the potential growth of multiple companies. Over the past year, Eli Lilly’s stock has surged by 90%, while Novo Nordisk has seen a 68% increase, indicating the strong performance of these key players.
Mazza dismisses concerns about investors missing out on the recent rally in the market, highlighting that the weight loss drug industry is still in its early stages of development. He envisions a bright future for GLP-1 drugmakers, likening their trajectory to that of AI-linked stocks like Nvidia. With a head start in the market and a focus on producing groundbreaking results, companies like Eli Lilly and Novo Nordisk are poised for long-term success in the field of diabetes and weight loss drugs.
Following the ETF’s launch last Tuesday, shares of Roundhill’s GLP-1 & Weight Loss ETF experienced a slight dip by almost 2% at the end of the week. While this may raise concerns among investors, Mazza remains optimistic about the future of the industry and the potential for significant growth. As more companies enter the market with advanced treatments and innovations, the landscape of weight loss drugs is expected to evolve rapidly, offering lucrative opportunities for investors willing to bet on the future of healthcare.